These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 36934365)

  • 21. Dietary Intake of Magnesium or Calcium and Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Patients.
    Wesselink E; Winkels RM; van Baar H; Geijsen AJMR; van Zutphen M; van Halteren HK; Hansson BME; Radema SA; de Wilt JHW; Kampman E; Kok DEG
    Nutrients; 2018 Mar; 10(4):. PubMed ID: 29570617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial.
    Lu W; Giobbie-Hurder A; Freedman RA; Shin IH; Lin NU; Partridge AH; Rosenthal DS; Ligibel JA
    Oncologist; 2020 Apr; 25(4):310-318. PubMed ID: 32297442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Newly identified chemotherapy-induced peripheral neuropathy in a childhood cancer survivorship clinic.
    Rodwin RL; Ross WL; Rotatori J; Allen K; Auerbach C; Balsamo LM; Kadan-Lottick NS
    Pediatr Blood Cancer; 2022 Mar; 69(3):e29550. PubMed ID: 34971076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial.
    Lemanska A; Harkin A; Iveson T; Kelly C; Saunders M; Faithfull S
    ESMO Open; 2023 Dec; 8(6):102063. PubMed ID: 37988949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study.
    Wang YJ; Chan YN; Jheng YW; Wu CJ; Lin MW; Tseng LM; Tsai YF; Liu LC
    Support Care Cancer; 2021 Jun; 29(6):2959-2971. PubMed ID: 33025227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin's lymphoma; symptom burden and quality of life.
    Eikeland SA; Smeland KB; Mols F; Fagerli UM; Bersvendsen HS; Kiserud CE; Fosså A
    Acta Oncol; 2021 Jul; 60(7):911-920. PubMed ID: 33905285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Similarities in the Neuropathy Phenotype of Cancer Survivors Who Received Different Classes of Chemotherapy Drugs.
    Miaskowski C; Levine JD; Paul SM; Cooper B; Abrams G; Topp K; Cheung S; Henderson-Sabes J; Conley YP; Snowberg K; Alfaro E; Quinn M; Kober KM
    J Pain; 2022 Sep; 23(9):1604-1615. PubMed ID: 35533976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy.
    Mizrahi D; Goldstein D; Trinh T; Li T; Timmins HC; Harrison M; Marx GM; Hovey EJ; Lewis CR; Friedlander M; Park SB
    Asia Pac J Clin Oncol; 2023 Feb; 19(1):243-249. PubMed ID: 35879821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
    Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
    JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors.
    Timmins HC; Li T; Goldstein D; Trinh T; Mizrahi D; Harrison M; Horvath LG; Friedlander M; Kiernan MC; Park SB
    J Cancer Surviv; 2022 Apr; 16(2):223-232. PubMed ID: 33641031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).
    Misawa S; Denda T; Kodama S; Suzuki T; Naito Y; Kogawa T; Takada M; Suichi T; Shiosakai K; Kuwabara S;
    BMC Cancer; 2023 Nov; 23(1):1098. PubMed ID: 37951905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impaired Postural Control and Altered Sensory Organization During Quiet Stance Following Neurotoxic Chemotherapy: A Preliminary Study.
    Monfort SM; Pan X; Loprinzi CL; Lustberg MB; Chaudhari AMW
    Integr Cancer Ther; 2019; 18():1534735419828823. PubMed ID: 30741022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term peripheral neuropathy symptoms in breast cancer survivors.
    Mustafa Ali M; Moeller M; Rybicki L; Moore HCF
    Breast Cancer Res Treat; 2017 Nov; 166(2):519-526. PubMed ID: 28791499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study.
    Engvall K; Gréen H; Fredrikson M; Lagerlund M; Lewin F; Åvall-Lundqvist E
    Breast Cancer Res Treat; 2022 Oct; 195(3):379-391. PubMed ID: 35941422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy.
    Kleckner IR; Jusko TA; Culakova E; Chung K; Kleckner AS; Asare M; Inglis JE; Loh KP; Peppone LJ; Miller J; Melnik M; Kasbari S; Ossip D; Mustian KM
    Breast Cancer Res Treat; 2021 Sep; 189(2):521-532. PubMed ID: 34191201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Structural Equation Approach With the Theory of Unpleasant Symptoms.
    Kim M; Jung MS
    Cancer Nurs; 2021 Mar-Apr 01; 44(2):145-153. PubMed ID: 31833921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.
    Zenatri M; Perennec T; Michon C; Gernier F; Grellard JM; Piloquet FX; Dubot-Poitelon C; Kalbacher E; Tredan O; Augereau P; Pautier P; Fey L; Joly F; Frenel JS
    Gynecol Oncol; 2024 Aug; 187():139-144. PubMed ID: 38776631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review.
    Timmins HC; Mizrahi D; Li T; Kiernan MC; Goldstein D; Park SB
    J Cancer Surviv; 2023 Feb; 17(1):222-236. PubMed ID: 33438175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy.
    Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB
    Gait Posture; 2021 Sep; 89():178-185. PubMed ID: 34320441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy.
    Winters-Stone KM; Horak F; Jacobs PG; Trubowitz P; Dieckmann NF; Stoyles S; Faithfull S
    J Clin Oncol; 2017 Aug; 35(23):2604-2612. PubMed ID: 28586243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.